Back

Favorable effects of sacubitril/valsartan treatment on cardiac autonomic function parameters in patients with heart failure and reduced ejection fraction

9 May 2026 (09:30 - 10:30)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - heart failure with HFrEF (2) Heart Failure with Reduced Ejection Fraction (HFrEF) HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Predrag Kekovic

Prokuplje (Serbia)

7 More presentations in this session

Presentation thumbnail
Integrating oxygen uptake efficiency slope and right ventricular stroke work index in the assessment of right ventricular function in advanced heart failure with reduced ejection fraction
Doctor D. Kosevic (Belgrade, RS)
Abstract Slides
Presentation thumbnail
Patients' experiences of home-based monitoring and standardized titration for heart failure with reduced ejection fraction
Ms K. Odefjord (Gothenburg, SE)
Abstract Slides
Presentation thumbnail
Selective inhibition of microRNA-132 with CDR132L in patients with heart failure with reduced/mildly reduced ejection fraction and left ventricular hypertrophy: the 8282-Reduced trial
Professor J. Bauersachs (Hannover, DE)
Abstract Slides
Presentation thumbnail
Are we meeting the guidelines? : a review on management of heart failure patients in a general hospital in UK
Doctor I. Ahmed (Preston, GB) Doctor C. Withana (Colombo, LK)
Abstract Slides
Presentation thumbnail
Beneficial effects of TX45, a long-acting Fc-relaxin fusion, on right ventricular-pulmonary artery coupling in patients with pulmonary hypertension due to HFrEF
Doctor R. Rogers (US)
Abstract Slides

Access the full session

Session thumbnail
ePosters in chronic heart failure - heart failure with HFrEF (2)

The Event

Event poster

Heart Failure 2026

9 May 2026 09:30 CET
You may be interested in
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023
thumbnail
Webinar
Advanced heart failure therapy in HF patients with preserved and mildly reduced ejection fraction
thumbnail
Congress Session
Targetting the pathophysiology of HFrEF

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources